DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Smith-McCort dysplasia — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSmith-McCort dysplasia maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for smith-mccort dysplasia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
RAB33B, member RAS oncogene family (RAB33B) — RAB33B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gtpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6Y09 · 2.4 Å · ligand GUANOSINE-5'-TRIPHOSPHATE (GTP). Experimental structure, not a prediction.
What the evidence adds up to
Smith-McCort dysplasia is a rare autosomal recessive skeletal disorder. It is allelic to Dyggve-Melchior-Clausen dysplasia; both share spondylo-epi-metaphyseal dysplasia and a distinctive lacy appearance of the iliac crest on radiographs. The two conditions are distinguished by the presence of intellectual disability and microcephaly in Dyggve-Melchior-Clausen and normal cognition in Smith-McCort. Genetic heterogeneity has been confirmed in Smith-McCort: mutations in DYMECLIN (the DYM gene) cause both disorders, and loss-of-function mutations in RAB33B, a gene involved in Golgi trafficking, have been identified as a second cause. A 2017 study reported three additional Smith-McCort patients with four novel RAB33B variants, including homozygosity for c.211C>T (p.R71*), homozygosity for c.365T>C (p.F122S), and compound heterozygosity for c.48delCGGGGCAG (p.G17Vfs*58) and c.490C>T (p.Q164*). A 2013 study described a patient with a loss-of-function mutation in the GTP-binding domain of RAB33B.
A 1979 case report described a 13-year-old boy with short-trunked dwarfism, normal intelligence, and the characteristic flattening of vertebral bodies and lacy iliac crest sign. A 2015 case report of a 23-year-old female noted enamel hypoplasia as part of the disorder and stated that orofacial characteristics are poorly described in the literature. A 2008 report described a female newborn with Marshall-Smith syndrome who also had septo-optic dysplasia; this is a different syndrome and not directly relevant to Smith-McCort. A 2025 case report title mentions Dyggve-Melchior-Clausen disease combined with Smith-McCort dysplasia but provides no patient numbers or outcome data.
No therapeutic trials, no drug interventions, and no survival or response rate data appear in any of these abstracts. The literature consists entirely of case reports and genetic studies. What is missing is any clinical trial, any drug-repurposing study, any animal model testing a pharmacological intervention, and any patient stratification beyond the known genetic subtypes. There is no evidence that any drug has been tested in Smith-McCort dysplasia.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics Part A · 2017 · 22 citations
Additional three patients with Smith‐McCort dysplasia due to novel <i>RAB33B</i> mutations
American Journal of Medical Genetics Part A · 2008 · 14 citations
Marshall–Smith syndrome and septo‐optic dysplasia: An unreported association
AbstractMarshall-Smith syndrome is characterized by advanced bone age, failure to thrive, respiratory problems, dysmorphic facial features, and variable mental retardation. Less than 40 cases have been reported in the literature, mostly as single case reports or small series. We describe a female newborn who, in addition to demonstrating many of the well described features of Marshall-Smith syndrome, had septo-optic dysplasia.
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · 1979 · 7 citations
Smith-McCort-Syndrom
AbstractAn 13-year-old mentally normal boy with short-trunked dwarfism is discribed as a case of the Smith-McCort syndrome (SMC-syndrome). His disease has been observed radiologically, clinically an histologically for many years. According to Spranger (23) this disorder differs from the Dyggve-Melchior-Clausen disease (DMC-syndrome) by lacking oligophrenia. Beside a characteristic flattening of the vertebral bodies both syndromes show a lacelike appearance of the iliac crest (crest sign) as a significant radiological sign. Both syndromes appear to be inherited as an autosomal recessive trait.
AbstractSmith-McCort dysplasia is a disorder with skeletal features identical to those of Dyggve-Melchior-Clausen syndrome but with normal intelligence and no microcephaly. Although both are associated with mutations in the Golgi protein DYMECLIN, genetic heterogeneity has been suspected for SMC. The study describes an SMC patient with a loss-of-function mutation in the GTP-binding domain of RAB33B, which is involved in Golgi trafficking. These data confirm the genetic heterogeneity of SMC and highlight the role of Golgi transport in the pathogenesis of SMC/DMC.
International Journal of Advanced Research · 2025 · 0 citations · open access
SKELETAL ANOMALIES AND BEYOND: A CASE REPORT OF DYGGVE MELCHIOR CLAUSEN DISEASE WITH SMITH MCCORT DYSPLASIA
AbstractDyggve Melchior Clausen (DMC) syndrome is an unusual form of uncommon autosomal recessive skeletal dysplasia.After its first occurrence in 1962, there has only been a hundred case reports to date with a mean incidence rate of0.1 per million.1 This article presents an account on a rare case report of Dyggve-MelchiorClausen disease combined with Smith Mccort Dysplasia.
Journal of Indian Academy of Oral Medicine and Radiology · 2015 · 0 citations · open access
Smith-McCort variant syndrome: A rare case with associated enamel hypoplasia
AbstractThe Smith-McCort syndrome (SMC), which was first described by Smith and McCort in 1958, is a rare form of osteochondrodysplasia, specifically a spondyloepimetaphyseal dysplasia. It is one of the rare syndromes that can present with skeletal dysplasia and mimic some of the common bone diseases. Enamel hypoplasia is a part of this disorder. Literature that describes the orofacial characteristics of this syndrome is lacking. Here we report a case of a 23-year-old female, who presented with characteristic orofacial features, along with skeletal abnormalities.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.